The stock of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) decreased by -$0.16 on Tuesday to finish at $9.86, down -1.60 percent. The last five days have seen an average of 2,703,160 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$2.53. The average number of shares traded over the last 20 days was 2,025,350, while the average volume over the last 50 days totaled 2,013,498.
IRWD stock dropped -4.92% since last month. On 08/10/23, the company’s shares reached a one-month low of $9.55. The stock touched a high of $12.66 on 01/06/23, after rallying from a low of $9.55 in 52 weeks. The price of IRWD stock has declined by -20.42% or -$2.53 this year, reaching a new high 3 times. Still, the stock price is down -22.12% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
IRWD stock investors should be aware that Ironwood Pharmaceuticals Inc. (IRWD) stock had its last reported insider trading activity 78 days ago on May 30. On May 30, Chief Executive Officer MCCOURT Thomas A sold 26,632 shares at $10.70 each. This transaction resulted in the insider making $284,962. On May 22, MCCOURT Thomas A sold 36,000 shares at a price of US$10.12. After the transaction, the insider now owns 784,916 shares. CMO,SVP,Head-Res&Drug Shetzline Michael had earlier sold 10,324 shares on May 22 for $10.12 a share. The transaction was completed for $104,479.
Valuation Metrics
Ironwood Pharmaceuticals Inc. (IRWD) has a trailing price-to-earnings (P/E) ratio of 9.81. Beta for the stock is 0.95. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.54.
Financial Health
For the three months ended June 29, Ironwood Pharmaceuticals Inc.’s quick ratio was 1.00, while its current ratio was 1.00, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $410.6 million and revenue of $410.6 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. IRWD’s return on assets (ROA) during the last 12 months has been -94.10%. There was a 16.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -228.70%.
Earnings Surprise
According to Ironwood Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $107.38 million, while revenues rose by 9.45% to $104.06 million. It was predicted that Ironwood Pharmaceuticals Inc.’s quarterly earnings would be -$6.71, but it ended up being $0.25, beating the consensus by -2,784.00%. EBITDA was -$1.08 billion for the quarter. At the end of Ironwood Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 950.0 million, while its total debt was $815.75 million. Equity owned by shareholders amounts to $156.03 million.
Technical Picture
Here’s a quick look at Ironwood Pharmaceuticals Inc.’s (IRWD) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 35.53%, suggesting the stock is Neutral, with a 63.58% historical volatility rate.
The stochastic %K and %D were 22.87% and 18.65% respectively, while the average true range (ATR) was 0.35. Based on the 14-day stochastic reading of 16.36%, the RSI (14) reading is 38.18%. On the 9-day MACD Oscillator, the stock is at -0.36, and the 14-day reading is at -0.62.
Analyst Ratings
In its analyst report released on September 02, 2022, CapitalOne began covering Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). The stock was rated as an Overweight by the brokerage firm. Analysts have assigned Ironwood Pharmaceuticals Inc. (IRWD) an Overweight rating. IRWD is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 1 other recommend it as a buy.
What is IRWD’s price target for the next 12 months?
The current consensus forecast for the stock is between $9.00 and $20.00, with a median target price of $15.00. In analyzing these forecasts, the average price target given by analysts for Ironwood Pharmaceuticals Inc. (IRWD) is $14.67.
